Entering text into the input field will update the search result below

Seagen's application seeking nod for colon cancer combo treatment gets FDA priority review

Sep. 19, 2022 9:01 AM ETSeagen Inc. (SGEN) StockBy: Anuron Mitra, SA News Editor

FDA headquarters in Washington DC.

JHVEPhoto

  • Seagen (NASDAQ:SGEN) on Monday said its supplemental new drug application (sNDA) for the accelerated approval of its inhibitor Tukysa in combination with monoclonal antibody trastuzumab to treat colon cancer had been accepted for priority review by the U.S. FDA.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SGEN--
Seagen Inc.